Fair Value Calculator Fair Value Calculator
EN DE

Veerhealth Care Limited (511523) Fair Value & Analysis

Other · IN · Market cap ₹52.0M

VC Veerhealth Care Limited 511523 · BSE
Price₹32.57
Fair Value₹57.92
Upside+77.8%
Quality62/100
Watch Veerhealth Care Limited for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹43.44 – ₹72.40

Fair value as of: Jul 4, 2026

From 14 valuation models · updated today

Share price +35.8% over the past month.

Price vs Fair Value (12 months)

₹32.57 ₹16.96 Fair Value ₹57.92 Jul 2025 Jul 2026

12‑month range ₹16.96 – ₹32.57 · fair‑value band ₹43.44 – ₹72.40 · the ₹32.57 price screens below the ₹57.92 fair value. As of Jul 4, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Veerhealth Care Limited (511523) currently trades at ₹32.57, while our model-based Fair Value estimate is ₹57.92 — implying the stock looks roughly 77.8% undervalued today. We read business quality at 62/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Net debt stands at ₹41.2M. The stock trades on a trailing P/E of 13.2. Fundamentals as of Jul 4, 2026

Key figures & financial health

Free cash flow −₹6.6M FY2026
P/E ratio 13.2
EPS (TTM) ₹0.5678
Net debt ₹41.2M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.

About the company

Veerhealth Care Limited manufactures and markets ayurvedic medicines in India. The company also offers tablets, syrups, ointments, powders, oils, shampoos, cosmetics, and toothpastes. It also exports its products. The company was formerly known as Niyati Industries Limited and changed its name to Veerhealth Care Limited in September 2013. Veerhealth Care Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Veerhealth Care Limited reported revenue of ₹325M in FY2026 versus ₹96.3M in FY2022, a compound +35.5%/yr. Reported net income was ₹5.4M in FY2026.

Revenue +35.5%/yr
FY22 ₹96.3M
FY23 ₹133M
FY24 ₹132M
FY25 ₹167M
FY26 ₹325M
Net income
FY22 −₹736K
FY23 ₹15.8M
FY24 ₹4.1M
FY25 ₹3.9M
FY26 ₹5.4M

Is 511523 fairly valued? → Check now

Similar stocks

6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).

Stock Price Fair Value vs Fair Value
There MOH €521.90 €269.92 -48%
Sony Corporation SON1 €17.58 €39.38 +124%
Federal Home Loan Mortgage Corporation FREJO $16.84 $64.93 +286%
533278 533278 ₹438.60 ₹720.31 +64%
Nestl?? India Limited 500790 ₹1,459 ₹279.60 -81%
540376 540376 ₹3,993 ₹1,806 -55%

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Veerhealth Care Limited (511523) undervalued?
As of Jul 4, 2026, our model estimates a fair value of ₹57.92 versus a price of ₹32.57 — about +78% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 511523?
Our model-based fair value for Veerhealth Care Limited is ₹57.92 (as of Jul 4, 2026), built from audited fundamentals. The current price is ₹32.57.
What is the quality score of 511523?
Veerhealth Care Limited has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of 511523?
The net profit margin of Veerhealth Care Limited is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.